Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

Kenneth B. Gordon, Andrew Blauvelt, Kim Papp et al. · New England Journal of Medicine · 2016 · 838 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

C.E.M. Griffiths, Kristian Reich, Mark Lebwohl et al. · The Lancet · 2015 · 831 citations

Medicine, Immunology, Pharmacotherapy +10

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)

Kim Papp, C. Leonardi, Andrew Blauvelt et al. · British Journal of Dermatology · 2017 · 94 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Initial results of ixekizumab efficacy and safety in real‐world plaque psoriasis patients: a multicentre retrospective study

Gustavo Deza, J. Notario, Anna López‐Ferrer et al. · Journal of the European Academy of Dermatology and Venereology · 2018 · 61 citations

Medicine, Dermatology, Pharmacotherapy +13

Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies

Jorge R. Georgakopoulos, Michelle Phung, Arvin Ighani et al. · Journal of the American Academy of Dermatology · 2018 · 54 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17